[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352726-105":59,"doc-detail-352726-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nivolumab-for-unresectable-cutaneous-epithelial-malignancies-an-open-label-single-arm-multi-centre-phase-ii-trial-nmsc-pd1","Nivolumab for unresectable cutaneous epithelial malignancies - an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1)","","Data in East Asian patients and in other epithelial skin cancers, including extramammary Paget’s disease and adnexal carcinomas, are scarce. A phase II, multicentre, open-label, single-arm trial evaluated nivolumab in Japanese adults with unresectable or recurrent epithelial cutaneous malignancies. Nivolumab 480 mg was given every 4 weeks up to 26 cycles; primary endpoint was overall response rate by blinded independent central review. Thirty-one patients were enrolled: ORR 22.6% and disease control 54.8%. Responses were durable with median duration 21.3 months; toxicity was manageable.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nivolumab-for-unresectable-cutaneous-epithelial-malignancies-an-open-label-single-arm-multi-centre-phase-ii-trial-nmsc-pd1/352726/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nivolumab-for-unresectable-cutaneous-epithelial-malignancies-an-open-label-single-arm-multi-centre-phase-ii-trial-nmsc-pd1/352726.png","ImageObject",300,407,{"name":92,"@type":93},"Aria Callaghan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the primary endpoint of the phase II trial?","Question",{"text":113,"@type":114},"Overall response rate (ORR) assessed by blinded independent central review using RECIST v1.1.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Who were the participants in this study?",{"text":118,"@type":114},"Adults (≥20 years) with histologically confirmed unresectable or recurrent epithelial cutaneous malignancies, ECOG performance status 0–1, and at least one measurable lesion.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the key efficacy results?",{"text":122,"@type":114},"Among 31 enrolled patients, ORR by BICR was 22.6% (7/31) and disease control rate was 54.8% (17/31). Responses were durable with a median duration of 21.3 months.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352726,1790416993,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962084926284,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Nakamura et al. BMC Cancer (2026) 26:467 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15829-2](https://doi.org/10.1186/s12885-026-15829-2)  \nRESEARCH Open Access  \nNivolumab for unresectable cutaneous   epithelial malignancies: an open-label, singlearm, multi-centre, phase II trial (NMSC-PD1)  \nYoshio Nakamura1, Naoya Yamazaki2, Kenjiro Namikawa2, Hiroshi Uchi3, Shoichiro Mori4, Mariko Ogawa-Momohara4, Taku Fujimura5, Tatsuya Takenouchi6, Mana Kurimoto7, Yuki Yamamoto7, Atsushi Otsuka8, Kenji Kabashima8, Takayuki Fusumae 1, Ikuko Hirai 1, Keiji Tanese1,9, Yasuko Saito1, Masayuki Amagai1, Ryo Takemura10, Yasunori Sato10 and Takeru Funakoshi 1*  \nAbstract  \nBackground Data in East Asian patients and in other epithelial skin cancers, including extramammary Paget’s disease (EMPD) and adnexal carcinomas, are scarce. Therefore, we conducted a phase II trial of nivolumab in Japanese patients with advanced non-melanoma skin cancers (NMSCs) .  \nPatients and methods This multicentre, open-label, single-arm phase II study enrolled adults (≥ 20 years) with histologically confirmed unresectable or recurrent epithelial cutaneous malignancies, Eastern Cooperative Oncology Group performance status 0–1, and at least one measurable lesion (RECIST v1 . 1) . Nivolumab 480 mg was administered intravenously every 4 weeks for up to 26 cycles. The primary endpoint was overall response rate (ORR), assessed by blinded independent central review (BICR; RECIST v1 . 1) . Secondary endpoints included progression-free survival, overall survival, and safety.  \nResults Thirty-one patients were enrolled (20 cSCC, 4 EMPD, 2 BCC, 5 other NMSCs); median age was 73 years (range 58–86), and 71% were male. ORR by BICR was 22 . 6%(7/31), and the disease control rate was 54 . 8%(17/31) . Responses were durable, with a median duration of 21.3 months. In the cSCC cohort, median tumour mutational burden (TMB) was 9.0 mut/Mb, lower than in Western series; among three patients with TMB ≥30 mut/Mb, two achieved objective responses. Common adverse events included pyrexia, hypothyroidism, adrenal insufficiency, and pruritus. Conclusions Nivolumab showed durable antitumour activity with manageable toxicity in Japanese patients  \nwith advanced NMSCs, including rare non-cSCC. The lower ORR compared with Western trials may reflect intrinsic biological differences and support biomarker-driven, region-specific immunotherapy.  \nClinical trial registration jRCT2031190048; registered 2 July 2019.  \nKeywords Non-melanoma skin cancer, Nivolumab, Programmed death-1, Squamous cell carcinoma, Epithelial skin malignancy  \n*Correspondence: Takeru Funakoshi [takeruf@keio.jp](takeruf@keio.jp)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nNakamura et al. BMC Cancer (2026) 26:467  \nIntroduction  \nCutaneous epithelial malignancies comprise ","cbCaiumAxHLRvdWV","https://ap.wps.com/l/cbCaiumAxHLRvdWV","pdf",1764341,13,"English","# Abstract\n## Background\n## Patients and methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the primary endpoint of the phase II trial?\",\"answer\":\"Overall response rate (ORR) assessed by blinded independent central review using RECIST v1.1.\"},{\"question\":\"Who were the participants in this study?\",\"answer\":\"Adults (≥20 years) with histologically confirmed unresectable or recurrent epithelial cutaneous malignancies, ECOG performance status 0–1, and at least one measurable lesion.\"},{\"question\":\"What were the key efficacy results?\",\"answer\":\"Among 31 enrolled patients, ORR by BICR was 22.6% (7/31) and disease control rate was 54.8% (17/31). Responses were durable with a median duration of 21.3 months.\"}]","Nivolumab for unresectable cutaneous epithelial malignancies - an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1) | PDF",1790101121,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17e849f81b9602bbff57f64793278cb8.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77636c026fb7724e7810f60789b0bca8.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f622088249ba0a11a0c08431263ab4aa.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5394ee8531866998496855baf1e5dbe8.webp",980,1306]